Louis G. Lange - Dec 29, 2023 Form 3/A Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Director
Signature
/s/ Louise Kooij by Power of Attorney for Louis G. Lange
Stock symbol
NAMS
Transactions as of
Dec 29, 2023
Transactions value $
$0
Form type
3/A
Date filed
1/25/2024, 05:00 PM
Date Of Original Report
Dec 29, 2023
Previous filing
Oct 4, 2022
Next filing
Jan 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NAMS Ordinary Shares 19.9K Dec 29, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NAMS Warrant (right to buy) Dec 29, 2023 Ordinary Shares 44.6K $11.50 Direct F2
holding NAMS Option (right to buy) Dec 29, 2023 Ordinary Shares 85K $10.00 Direct F3, F4
holding NAMS Option (right to buy) Dec 29, 2023 Ordinary Shares 85.2K Direct F5, F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment is being filed to include 10,000 ordinary shares inadvertently omitted from the Form 3 filed by the Reporting Person on December 29, 2023.
F2 This amendment is being filed to include warrants to purchase ordinary shares inadvertently omitted from the Form 3 filed by the Reporting Person on December 29, 2023.
F3 The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date. 9,878 shares underlying the option have been exercised by the Reporting Person.
F4 This amendment is being filed to remove options to purchase 9,878 ordinary shares inadvertently included in the Form 3 filed by the Reporting Person on December 29,2023.
F5 The option was granted on November 22, 2022 to replace an option originally granted on July 8, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the option vested on June 1, 2022, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
F6 This amendment is being filed to include options to purchase 9,878 ordinary shares inadvertently omitted from the Form 3 filed by the Reporting Person on December 29, 2023.
F7 The exercise price of the option is Euro 1.16392.